U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Public Webinar Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision Making – Draft Guidance - 05/04/2023
  1. News & Events for Human Drugs

Virtual | Virtual

Event Title
Public Webinar Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision Making – Draft Guidance
May 4, 2023

Date:
May 4, 2023
Time:
1:00 p.m. - 3:00 p.m. ET

On May 4, 2023, the U.S. Food and Drug Administration (FDA) hosted a webinar for patients, industry, and other interested stakeholders to discuss and answer questions about the draft guidance: Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision Making.

Webinar Materials:

Background:

Guidance 4 is the fourth in a series of four methodological patient-focused drug development (PFDD) guidance documents that describe how stakeholders (patients, caregivers, researchers, medical product developers, and others) can collect and submit patient experience data and other relevant information from patients and caregivers to be used for medical product development and regulatory decision-making.

Guidance 4 focuses on methods, standards, and technologies for collecting and analyzing COA data, including selecting COA-based endpoints and determining clinically meaningful differences in these endpoints.

Public Docket:

Interested stakeholders are invited to submit comments on the draft guidance to the public docket. The public docket will close on July 5, 2023.

Related Information:

CDER Patient-Focused Drug Development

Back to Top